Track Replimune Group, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Replimune Group, Inc. REPL · Stock Open Replimune Group, Inc. in new tab

21.89 USD
EPS
-2.79
P/B
10.13
ROE
-115.80
Beta
0.93
Target Price
23.33 USD
Loading chart...
Key Metrics
Earnings dateFeb. 2, 2027
EPS-2.79
Book Value2.16
Price to Book10.13
Debt/Equity62.11
% Insiders2.693%
Estimates
Forward P/E-32.63
Forward EPS-0.67
Target Mean Price23.33

DCF valuation

Model fair value for Replimune Group, Inc. (REPL)
Result
Sign in to run the valuation for REPL.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
6 analysts · consensus None · mean target 23.33 USD (low 14.00, high 31.00) · as of 14 Nov 2026
Low 14.00
Mean 23.33
High 31.00
Price 21.89
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Replimune Group, Inc. Logo Replimune Group, Inc. Analysis (REPL)

United States Health Care Official Website Stock

Is Replimune Group, Inc. a good investment? Replimune Group, Inc. (REPL) is currently trading at 21.89 USD. Market analysts have a consensus price target of 23.33 USD. This suggests a potential upside from current levels.

Earnings Schedule: Replimune Group, Inc. is expected to release its next earnings report on Feb. 2, 2027. The market consensus estimate for Forward EPS is -0.67.

Investor FAQ

Does Replimune Group, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Replimune Group, Inc.?

Replimune Group, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 2, 2027. The company currently has a trailing EPS of -2.79.

Company Profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.

Exchange Ticker
MUN (Germany) 7R8.MU
FRA (Germany) 7R8.F
NMS (United States) REPL
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion